Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 5413: Intracellular ATP reduction by an artificial protein as a novel approach to cancer therapy

Dennis Datuin, Matt Hamada, Bernardo Chavira, Andrew Fontes, Nagaraj Vinay Janthakahalli and Shaleen Korch
Dennis Datuin
Midwestern University, Glendale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matt Hamada
Midwestern University, Glendale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernardo Chavira
Midwestern University, Glendale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Fontes
Midwestern University, Glendale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nagaraj Vinay Janthakahalli
Midwestern University, Glendale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaleen Korch
Midwestern University, Glendale, AZ.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-5413 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

Introduction: The use of chemotherapeutic agents that target key metabolic processes in cancer cells is an important therapeutic strategy. As a result of reduced mitochondrial activity, adenine triphosphate (ATP) is produced mainly by aerobic glycolysis and lactic acid fermentation in the cytosol of cancer cells (Warburg effect). Since ATP is a vital energy carrier that is crucial for various biochemical reactions in cancerous cells, interfering with the production/availability of ATP offers a new approach to cancer therapy. To assess this idea, a man-made synthetic ATP-binding protein, DX, was tested as a novel cancer therapy. Hypothesis: Reduced ATP availability, due to the expression of DX in HeLa cells, will negatively affect cellular metabolism and viability. Methods: For controlled expression, DX was cloned into the pcDNA™5/TO expression vector (with an N-terminal FLAG tag), whose expression is driven by a tetracycline-regulated cytomegalovirus promoter. Cultured T-REx™ HeLa cells (which stably express the tetracycline repressor protein) were transfected with pcDNA™5/TO::DX. As a control for transfection and DX expression, T-REx™ HeLa cells were transfected with pcDNA™5/TO/lacZ and cultured under identical conditions. The impact of DX expression on cell viability and morphology was assessed using a tetrazolium-based colorimetric cell viability assay and by light and fluorescent microscopy. To assess the impact of ATP depletion in combination with currently used anti-cancer agents on HeLa cell viability, toxicity assays were performed comparing Doxorubicin, Paclitaxel, or Gemcitabine treatment alone or in combination with DX. Results: HeLa cells expressing DX experienced reduced viability and altered morphology compared to cells expressing lacZ alone. These results suggest that ATP depletion potentiate cell death in HeLa cells. HeLa cells treated singly with DX do not possess the same level of toxicity as compared with the tested chemotherapy agents. Of the chemotherapy agents assayed, DX displayed a synergistic effect with Doxorubicin to reduce cell viability. Conclusion: Reduced intracellular ATP levels, mediated by a synthetic ATP-binding protein, negatively affects the viability of cervical cancer cells. The reduction in ATP, and the consequence of this on biochemical pathways and cell viability requires further investigation. We suggest that artificial proteins, such as DX, could be used to control and regulate specific targets in metabolic pathways and represents a new approach for cancer chemotherapy.

Citation Format: Dennis Datuin, Matt Hamada, Bernardo Chavira, Andrew Fontes, Nagaraj Vinay Janthakahalli, Shaleen Korch. Intracellular ATP reduction by an artificial protein as a novel approach to cancer therapy. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5413. doi:10.1158/1538-7445.AM2015-5413

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 5413: Intracellular ATP reduction by an artificial protein as a novel approach to cancer therapy
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 5413: Intracellular ATP reduction by an artificial protein as a novel approach to cancer therapy
Dennis Datuin, Matt Hamada, Bernardo Chavira, Andrew Fontes, Nagaraj Vinay Janthakahalli and Shaleen Korch
Cancer Res August 1 2015 (75) (15 Supplement) 5413; DOI: 10.1158/1538-7445.AM2015-5413

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 5413: Intracellular ATP reduction by an artificial protein as a novel approach to cancer therapy
Dennis Datuin, Matt Hamada, Bernardo Chavira, Andrew Fontes, Nagaraj Vinay Janthakahalli and Shaleen Korch
Cancer Res August 1 2015 (75) (15 Supplement) 5413; DOI: 10.1158/1538-7445.AM2015-5413
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Kinase Inhibitors and Other Targets

  • Abstract 5415: Therapeutic effects of TOPK inhibitor on triple-negative breast cancer
  • Abstract 5404: PAK4 allosteric modulators (PAMs) repress the Wnt/β-catenin signaling pathway and tumor growth
  • Abstract 5416: Activity of the pan-PIM kinase inhibitor INCB053914 in models of acute myelogenous leukemia
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement